Josep Domingo‐Domenech

Author

Icahn School of Medicine at Mount Sinai ORCID

Also Known As

J Domingo-Domenech, J. Domingo-Domenech, J. Domingo-Domènech, J. Domingo-Doménech, Josep Domingo-Domenech, Josep Domingo-Domènech, Josep Domingo-Doménech, Josep Domingo‐Domenech, Josep M. Domingo Domenech

Publications

3.4K

Citations

H-Index

Concepts

All Affiliations

Icahn School of Medicine at Mount Sinai Consorci Institut D'Investigacions Biomediques August Pi I Sunyer Thomas Jefferson University Universitat de Barcelona Sidney Kimmel Cancer Center

About

Josep Domingo‐Domenech is an author at Icahn School of Medicine at Mount Sinai specializing in medicine, urology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	13	1.2K
2	Cell Biology	10	10	1.1K
3	Engineering	2	2	79
4	Health Sciences	2	2	156
5	Biomedical Engineering	2	2	79

Josep Domingo‐Domenech

Publications

2.5K

Citations

H-Index

Page 1

	Year	Citations
Suppression of Acquired Docetaxel Resistance in Prostate Cancer through Depletion of Notch- and Hedgehog-Dependent Tumor-Initiating Cells Josep Domingo‐Domenech, Samuel J. Vidal, Verónica Rodríguez-Bravo, Cancer Cell Lineage PlasticityUrologyOncologyAcquired Docetaxel ResistanceMedicine	2012	432
EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer Li Wang, Abdel Saci, Péter M. Szabó, Nature Communications	2018	319
Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma Victoria Tovar, Helena Cornellà, Agrin Moeini, Gut	2015	206
Interleukin 6, a Nuclear Factor-κB Target, Predicts Resistance to Docetaxel in Hormone-Independent Prostate Cancer and Nuclear Factor-κB Inhibition by PS-1145 Enhances Docetaxel Antitumor Activity Josep Domingo‐Domenech, Cristina Oliva, Ana Rovira, Clinical Cancer Research	2006	169
A Targetable GATA2-IGF2 Axis Confers Aggressiveness in Lethal Prostate Cancer Samuel J. Vidal, Verónica Rodríguez-Bravo, S. Aidan Quinn, Cancer Cell UrologyMedicineCancer BiologyProstatic DiseaseLethal Prostate Cancer	2015	153
Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import Verónica Rodríguez-Bravo, Raffaella Pippa, Won-Min Song, Cell UrologyPerineural InvasionPom121-driven E2f1Cancer Cell BiologyProstatic Disease	2018	150
Distinct Expression Profiles of p63 Variants during Urothelial Development and Bladder Cancer Progression Orit Karni-Schmidt, Mireia Castillo-Martín, Nataliya Gladoun, American Journal Of Pathology UrologyGenitourinary CancerMedicineDistinct Expression ProfilesCancer Genomics	2011	143
Activation of nuclear factor-κB in human prostate carcinogenesis and association to biochemical relapse Josep Domingo‐Domenech, Begoña Mellado, David Truan, British Journal of Cancer	2005	113
Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes Matthew D. Galsky, Huan Wang, Noah M. Hahn, European Urology Metastatic Urothelial CancerUrologyGenitourinary CancerMedicineClinical Trials	2017	113
Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells Jordi Codony‐Servat, M. Tapia, Marta Bosch, Molecular Cancer Therapeutics	2006	106

Page 1